SynAct Pharma AB (SYNACT) - Net Assets

Latest as of March 2026: Skr193.75 Million SEK ≈ $20.85 Million USD

Based on the latest financial reports, SynAct Pharma AB (SYNACT) has net assets worth Skr193.75 Million SEK (≈ $20.85 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr237.88 Million ≈ $25.60 Million USD) and total liabilities (Skr44.13 Million ≈ $4.75 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SynAct Pharma AB tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr193.75 Million
% of Total Assets	81.45%
Annual Growth Rate	66.08%
5-Year Change	716.0%
10-Year Change	528.9%
Growth Volatility	2393.93

SynAct Pharma AB - Net Assets Trend (2014–2025)

This chart illustrates how SynAct Pharma AB's net assets have evolved over time, based on quarterly financial data. See SynAct Pharma AB (SYNACT) defensive interval to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for SynAct Pharma AB (2014–2025)

The table below shows the annual net assets of SynAct Pharma AB from 2014 to 2025. For live valuation and market cap data, see SynAct Pharma AB market cap and net worth.

Year	Net Assets	Change
2025-12-31	Skr170.29 Million ≈ $18.33 Million	-20.49%
2024-12-31	Skr214.17 Million ≈ $23.05 Million	+21.56%
2023-12-31	Skr176.19 Million ≈ $18.96 Million	+39.26%
2022-12-31	Skr126.52 Million ≈ $13.62 Million	+506.26%
2021-12-31	Skr20.87 Million ≈ $2.25 Million	+31.52%
2020-12-31	Skr15.87 Million ≈ $1.71 Million	+17.51%
2019-12-31	Skr13.50 Million ≈ $1.45 Million	+30.94%
2018-12-31	Skr10.31 Million ≈ $1.11 Million	-20.13%
2017-12-31	Skr12.91 Million ≈ $1.39 Million	-52.32%
2016-12-31	Skr27.08 Million ≈ $2.91 Million	+8361.75%
2015-12-31	Skr320.00K ≈ $34.44K	-50.16%
2014-12-31	Skr642.00K ≈ $69.09K	--

Equity Component Analysis

This analysis shows how different components contribute to SynAct Pharma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 67926200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	Skr6.67 Million	3.91%
Other Comprehensive Income	Skr12.11 Million	7.11%
Other Components	Skr835.34 Million	490.54%
Total Equity	Skr170.29 Million	100.00%

SynAct Pharma AB Competitors by Market Cap

The table below lists competitors of SynAct Pharma AB ranked by their market capitalization.

Company	Market Cap
Jayant Agro Organics Limited NSE:JAYAGROGN	$70.27 Million
Kawan Food Bhd KLSE:7216	$70.34 Million
Cheviot Company Limited NSE:CHEVIOT	$70.36 Million
Jinhui Shipping and Transportation Limited OL:JIN	$70.36 Million
Grupo Mexicano de Desarrollo S.A.B MX:GMD	$70.26 Million
Birla Cable Limited NSE:BIRLACABLE	$70.25 Million
Demco Public Company Limited BK:DEMCO	$70.22 Million
Welspun Investments and Commercials Limited NSE:WELINV	$70.15 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in SynAct Pharma AB's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 214,168,000 to 170,291,000, a change of -43,877,000 (-20.5%).
Net loss of 110,826,000 reduced equity.
New share issuances of 92,210,000 increased equity.
Other comprehensive income decreased equity by 6,444,000.
Other factors decreased equity by 18,817,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Skr-110.83 Million	-65.08%
Share Issuances	Skr92.21 Million	+54.15%
Other Comprehensive Income	Skr-6.44 Million	-3.78%
Other Changes	Skr-18.82 Million	-11.05%
Total Change	Skr-	-20.49%

Book Value vs Market Value Analysis

This analysis compares SynAct Pharma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.50x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2014-12-31	Skr-0.55	Skr11.66	x
2015-12-31	Skr-0.66	Skr11.66	x
2016-12-31	Skr2.28	Skr11.66	x
2017-12-31	Skr1.04	Skr11.66	x
2018-12-31	Skr0.75	Skr11.66	x
2019-12-31	Skr0.91	Skr11.66	x
2020-12-31	Skr0.73	Skr11.66	x
2021-12-31	Skr0.80	Skr11.66	x
2022-12-31	Skr4.59	Skr11.66	x
2023-12-31	Skr5.42	Skr11.66	x
2024-12-31	Skr5.42	Skr11.66	x
2025-12-31	Skr3.33	Skr11.66	x

Capital Efficiency Dashboard

This dashboard shows how efficiently SynAct Pharma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -65.08%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 0.00%
• Asset Turnover: 0.00x
• Equity Multiplier: 1.29x
Recent ROE (-65.08%) is above the historical average (-115.41%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2014	0.00%	0.00%	0.00x	0.00x	Skr-541.10K
2015	0.00%	0.00%	0.00x	0.00x	Skr-502.70K
2016	-57.08%	0.00%	0.00x	1.13x	Skr-18.16 Million
2017	-119.23%	0.00%	0.00x	1.18x	Skr-16.69 Million
2018	-227.35%	0.00%	0.00x	1.36x	Skr-24.48 Million
2019	-177.42%	0.00%	0.00x	1.76x	Skr-25.31 Million
2020	-167.32%	0.00%	0.00x	1.36x	Skr-28.14 Million
2021	-332.09%	0.00%	0.00x	1.84x	Skr-71.39 Million
2022	-78.41%	0.00%	0.00x	1.13x	Skr-111.86 Million
2023	-122.49%	0.00%	0.00x	1.29x	Skr-233.43 Million
2024	-38.47%	0.00%	0.00x	1.26x	Skr-103.82 Million
2025	-65.08%	0.00%	0.00x	1.29x	Skr-127.86 Million

Industry Comparison

This section compares SynAct Pharma AB's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $159,185,570
Average return on equity (ROE) among peers: -26.34%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
SynAct Pharma AB (SYNACT)	Skr193.75 Million	0.00%	0.23x	$70.27 Million
2cureX AB (2CUREX)	$74.34 Million	-25.47%	0.06x	$5.16 Million
Ascelia Pharma AB (publ) (ACE)	$237.06 Million	-16.83%	0.06x	$41.03 Million
AcouSort AB (ACOU)	$376.48K	28.69%	1.44x	$9.52 Million
Active Biotech AB (ACTI)	$46.67 Million	-106.88%	0.22x	$103.60 Million
Alzinova AB (ALZ)	$105.53 Million	-12.38%	0.06x	$8.00 Million
AlzeCure Pharma (ALZCUR)	$233.17 Million	-15.43%	0.02x	$46.62 Million
Annexin Pharmaceuticals AB (ANNX)	$15.57 Million	-63.12%	0.51x	$9.23 Million
Alligator Bioscience AB (ATORX)	$41.44 Million	0.00%	0.15x	$11.36 Million
BioInvent International AB (BINV)	$49.01 Million	-36.81%	0.66x	$163.58 Million
BioArctic AB (publ) (BIOA-B)	$788.68 Million	-15.19%	0.14x	$2.39 Billion

About SynAct Pharma AB

ST:SYNACT Sweden Biotechnology

Market Cap

$70.27 Million

Skr652.94 Million SEK

Market Cap Rank

#20673 Global

#372 in Sweden

Share Price

Skr11.66

Change (1 day)

+9.38%

52-Week Range

Skr10.66 - Skr24.95

All Time High

Skr143.40